[Treatment of essential arterial hypertension with a thiazide-spironolactone-reserpine derivative combination].
D000328:Adult; D000368:Aged; D001581:Benzothiadiazines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012110:Reserpine / Q000009:adverse effects; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use*; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*
D001581:Benzothiadiazines; D046948:Secologanin Tryptamine Alkaloids; D013148:Spironolactone; D012110:Reserpine
Traitement de l'hypertension artérielle essentielle par une association thiazide-spironolactone-dérivé réserpinique.